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Abstract
Background: Tumour stromal myofibroblasts can promote tumour invasion. As these cells are
genetically more stable than cancer cells, there has been enormous interest in developing targeted
molecular therapies against them. Chloride intracellular channel 4 (CLIC4) and reactive oxygen
species (ROS) have been linked with promoting stromal cell transdifferentiation in various cancers,
but little is known of their roles in ovarian cancer. In this study, we examined the functional roles
that both CLIC4 and ROS play in the process of ovarian cancer cell-stimulated or TGF-1 induced
fibroblast-to-myofibroblast transdifferentiation. We also examine whether it is possible to reverse
such a process, with the aim of developing novel therapies against ovarian cancer by targeting
activated transdifferentiated myofibroblasts.
Results: We demonstrate that TGF-1 induced or CMSKOV3 activate transdifferentiated
myofibroblasts (fibroblasts). These fibroblasts mimic "reactive" stromal myofibroblasts and
demonstrate significant up-regulation of CLIC4 expression and increased level of ROS production.
Blocking the production of ROS with an antioxidant consequently reduces the expression of
CLIC4, and is accompanied by disappearance of -smooth-muscle actin (-SMA), a myofibroblast
marker, suggesting ROS acts as a signalling molecule that promotes and enhances CLIC4 activities
in the myofibroblast transdifferentiaton process. Down-regulation of CLIC4 with a generic agent
or specific siRNA both significantly reduces the expression of factors related to the phenotypes
and functions of myofibroblasts, such as -SMA, hepatocyte growth factor (HGF) and vascular
endothelial growth factor (VEGF), thus reversing the myofibroblast phenotype back to fibroblasts.
These results convincingly show that ROS and CLIC4 are responsible for TGF-1 induced
fibroblast-to-myofibroblast transdifferentiaton and down-regulation of both is sufficient to block
transdifferentiated myofibroblasts.
Conclusion: Molecular targeting of ROS and CLIC4 has the potential to develop novel therapies
for ovarian cancer.
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Ovarian cancer is not only common (1 in 67 women), but
also is the most lethal gynaecological disease. It has, for
years, been dubbed as a "silent killer" -- causing vague and
non-specific symptoms until it is too advanced at the time
of diagnosis [1]. Thus, ovarian cancer causes more deaths
than any other type of gynaecological malignancies [1-3].
Even with the advent of modern treatments such as opti-
mal cytoreductive surgery and systemic combination of
chemotherapies, the 5-year survival rate for patients with
advanced ovarian cancer has improved little; it is currently
at as low as 10 - 30% [3].
Extensive studies have shed some lights on the complexity
of ovarian cancer, and increasing evidence indicates that
the disease development and progression are facilitated
by interactions between tumour cells and activated stro-
mal cells [4]. The tumour stroma (also referred to as "reac-
tive stroma") is characterized by marked alterations in the
phenotype and expression profile of "fibroblast-like
cells". These cells commonly express -smooth-muscle
actin (-SMA) and thus are termed as myofibroblasts
[5,6]. Stromal fibroblasts are located at the tumour border
near the invasion front. When these cells are activated by
the tumour, they have a more profound influence on the
development and progression of carcinomas than was
previously appreciated [7]. Recent studies on reactive
stroma in human breast carcinomas and in prostate can-
cer subjects have demonstrated that the co-culturing of
myofibroblasts with these tumour cells can promote
tumour invasion and angiogenesis [8,9]. Using an in vitro
tumour-stroma model of skin carcinogenesis, Cat and col-
leagues (2006) demonstrated that myofibroblasts are
recruited into cancer from different sources during cancer
development and the invasion progression [10,11]. These
cells were differentiated from the fibroblast population
within the epithelial stroma after stimulation by trans-
forming growth factor-1 (TGF-1) secreted by tumour
cells. Tumour-associated myofibroblasts could also be
transdifferentiated from non-malignant or epithelial
derived carcinoma cells via epithelial-mesenchymal tran-
sition [11]. In addition, myofibroblasts could be recruited
or derived from distant fibroblasts and bone marrow pro-
genitor cells [12,13]. Although it has been shown that the
conversion from fibroblasts to myofibroblasts constitutes
the major source of myofibroblasts in tumour stroma, the
molecular mechanisms underlying fibroblast-to-myofi-
broblast transdifferentiation is still not fully understood.
Many questions remain, including what molecules are
involved in the process and what roles are they playing?
A family of intracellular chloride channels comprises
seven highly homologous members (CLIC1-7). Recently,
it was reported that one of them, the chloride intracellular
channel 4 (CLIC4), a chloride channel of intracellular
organelles, regulates intracellular pH and cell volume.
Besides its presence on the organelle membrane, CLIC4
exists in soluble form in the cytoplasm and nucleus acting
as a signalling protein or channel regulator [14]. The tran-
scriptional level of CLIC4 is up-regulated when fibroblasts
are induced by TGF-1 and transdifferentiated into myofi-
broblasts, and more importantly CLIC4 is highly
expressed in myofibroblasts of breast cancers [15]. Results
from Littler and colleagues [16] shows that functional
activity of CLIC4 depends on its redox state and that oxi-
dative conditions enhance membrane binding and chan-
nel activity of CLIC4. More recent findings also reveal that
reactive oxygen species (ROS) can alter the level of gene
expression associated with cell differentiation, including
fibroblast-to-myofibroblast transdifferentiation and epi-
thelial-mesenchymal transition in liver fibrosis and some
cancers [10,17,18]. However, the role of ROS in ovarian
cancer and its relationship to CLIC4 in fibroblast-to-
myofibroblast transdifferentiation process is not well
understood. We hypothesized that the factors involved in
fibroblast-to-myofibroblast transdifferentiation, such as
tumour-cell-derived TGF-1, promote the generation of
intercellular ROS, which in turn acts as a signalling mole-
cule, and initiates up-regulation of CLIC4 expression, thus
triggering fibroblast-to-myofibroblast conversion. Agents
that block ROS and CLIC4 might inhibit such transdiffer-
entiation, which may delay myofibroblast-dependent
tumour progression. Understanding these molecular
interactions may assist with the development of novel
molecular targeted therapies for ovarian cancer.
To test the hypothesis, we designed an experiment model-
ling ovarian cancer fibroblast-to-myofibroblast transdif-
ferentiation and examined the pathway in which ROS and
CLIC4 participates in fibroblast-to-myofibroblast transi-
tion induced by TGF-1 or conditioned media from ovar-
ian cancer SKOV3 cells (CMSKOV3). Furthermore, special
agents were employed to down-regulate the production of
ROS and CLIC4 in transdifferentiated myofibroblasts and
such effects were assessed.
Results and Discussion
Myofibroblasts in the experimental ovarian cancer stroma 
have increased CLIC4 expression
Recent studies demonstrated that CLIC4 was markedly
up-regulated in serum- or TGF-1-stimulated fibroblasts
isolated from breast cancer. These fibroblasts have a gene
expression profile similar to myofibroblasts [15,19]. In
vivo, the level of CLIC4 expression in the normal ovarian
stroma is very low, but is significantly increased in the
stroma of breast, kidney, oesophagus and colon cancers
[20-22]. We hypothesised that CLIC4 may also play an
important functional role in causing stromal fibroblast to
myofibroblast transdifferentiation, which is critical in
ovarian cancer development and progression.Page 2 of 8
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othelial cells covering the ovarian surface and contiguous
with coelomic mesothelium. We recently showed that the
expression of CLIC4 was readily detected in epithelia and
stroma of these primary epithelial ovarian cancers in
96.7% (29/30) of patients. Moreover, the expression of
CLIC4 in cancer stroma was correlated with up-regulation
of a well-accepted myofibroblast marker, -SMA, which
was detected in 93.3% (28/30) of the same stroma (Yao et
al., manuscript in preparation).
In order to define the expression of CLIC4 in transdiffer-
enciated myofibroblasts we performed immunohisto-
chemical staining of CLIC4 and -SMA1 (Fig. 1A). We
used a myofibroblast conversion culture model where
ovarian primary fibroblasts and/or human fibroblast
MRC-5 cells were co-cultured with CMSKOV3 or TGF-1.
Fig. 1A showed that the myofibroblasts displayed a signif-
icant increase in CLIC4 expression both in the cytoplasm
and nucleus (p < 0.05) with co-expression of a myofibrob-
last marker, -SMA in the cytoplasm in the presence of
CMSKOV3 or 10 ng/ml TGF-1 compared with the serum-
free medium control (p < 0.05). Furthermore, the immu-
noblot and real time qRT-PCR data provides strong evi-
dence that the increased amounts of -SMA and CLIC4
expression in myofibroblasts were up-regulated both at
the transcription and protein levels (P < 0.05) (Fig. 1B).
These results confirmed that the expression of CLIC4 was
up-regulated during fibroblast to myofibroblast conver-
sion when induced by TGF-1 or activated by CMSKOV3
suggesting that CLIC4 directly participates in stromal
fibroblast activation in ovarian cancer.
ROS mediates up-regulation of CLIC4, which leads to 
myofibroblast transdifferentiation
More recent reports have suggested that ROS acts as a sig-
nalling molecule of TGF-1 in the regulation of myofi-
broblast differentiation in liver fibrosis and an in vitro
tumour-stroma model of skin carcinogenesis [10,17]. It
can alter gene expression levels by regulating the expres-
sion of multiple phenotypic markers, such as -SMA [10].
When we examined the intracellular ROS levels in MRC-5
fibroblasts treated with 10 ng/ml TGF-1 or CMSKOV3, we
showed a significant increase in the fluorescence intensity
using DCF-DA dye staining, indicating high levels of intra-
cellular ROS production (Fig. 2A). Simultaneously, the
high level of ROS was accompanied by up-regulation of -
SMA and CLIC4 expressions in the myofibroblasts. How-
ever, when the MRC-5 fibroblasts cells were pre-treated
with the antioxidant N-acetylcysteine (NAC), which
blocked the intracellular ROS, the up-regulation of -SMA
and CLIC4 expressions, stimulated by TGF-1 or
CMSKOV3, were also reduced at both mRNA and protein
levels (Fig. 2C). These results showed that not only -SMA
but also CLIC4 transcription and translation levels were
significantly up-regulated followed by generation of ROS
during TGF-1 induced fibroblast-to-myofibroblast dif-
ferentiation. This effect could be blocked by treatment
with the NAC. This is the first evidence that showed TGF-
1 or CMSKOV3 stimulated the production of cellular ROS
and CLIC4, which correlated with myofibroblast transdif-
ferentiation (Figure 2). Moreover, agents which inhibit
ROS alleviated the expression of CLIC4 and -SMA.
CLIC4 shares homology with that of the glutathione S-
transferase (GST) superfamily, suggesting its function may
depend on the cellular redox state. A cysteine at position
35 preceding the N-terminal transmembrane domain is
redox sensitive and is modified by glutathione [16].
CLIC4 subcellular locations are critical in its physiological
functions [23]. Since CLIC4 is upregulated in myofibrob-
lasts, we further assessed the expression of CLIC4 in the
nucleus and cytoplasm during myofibroblast differentia-
tion using Western blot. As shown in Fig. 2D, the expres-
sion of CLIC4 increased not only in the cytoplasm but
also in the nucleus, particularly when fibroblasts were
treated with TGF-1 or CMSKOV3. Pre-treatment with anti-
oxidant NAC also reduced both cytoplasmic and nuclear
CLIC4 expressions. Taken together, these data suggest that
TGF-1 or CMSKOV3 increases cellular ROS, which induces
up-regulation and activity of CLIC4, leading to myofi-
broblast transdifferentiation.
Down-regulation of CLIC4 reverses the myofibroblast 
phenotype
A previous study reported that up-regulation and nuclear
translocation of CLIC4 was responsible for expression of
keratinocytic differentiation markers by altering chloride
content and pH of the nucleus. Treatment of keratinocytes
with a chloride channel inhibitor blocked the chloride ion
flux by nuclear-specific CLIC4 and reduced the expression
level of differentiation biomarker K10 [21]. In addition to
the channel activity of CLIC4, there was a report that
showed CLIC4 could promote cytoskeleton function by
interaction with dynamin, tubulin, actin and 14-33 pro-
teins [24]. Recombinant CLIC4 was shown to reduce cell
motility in fibroblasts [15]. Thus, the relationship
between CLIC4 and -SMA seems to be important to the
physiological function of myofibroblast cells. Since
CLIC4 is the only intracellular chloride channel that can
be induced by TGF-1 in fibroblasts [15], we used a chlo-
ride channel inhibitor, indanyloxyacetic acid 94 (IAA-94)
to inhibit the function of CLIC4 and found reduced
expression of -SMA and myofibroblast-mediated angio-
genesis factors. Using a CLIC4 specific siRNA, we further
demonstrated the consequential outcome of reduced
CLIC4 expression. When fibroblasts were transfected with
specific CLIC4 siRNA prior to treatment with TGF-1 or
CMSKOV3 CLIC4, siRNA efficiently down-regulated CLIC4
transcript levels by an average of 90%. The induction of -Page 3 of 8
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Molecular Cancer 2009, 8:78 http://www.molecular-cancer.com/content/8/1/78Immunohistochemical staining of CLIC4 and -SMAFigure 1
Immunohistochemical staining of CLIC4 and -SMA. (A). In cultured fibroblasts (control) and transdifferiated myofi-
broblasts (activated by CMSKOV3 (CM) and TGF-1). Scale bar, 50 m. (B) Western blot of MRC-5 cells or primary ovarian 
fibroblasts cultured in serum-free medium (control), in CM or TGF-1 for 48 hours.
 
SMA transcript induced by TGF-1 or CMSKOV3 was signif-
icantly blocked in CLIC4 siRNA-transfected fibroblasts
(Fig. 3A, B). At the protein level, immunoblot and
immunofluorescent data showed that silencing of CLIC4
prevented the expression of -SMA (Fig. 3C, D). These
results are in agreement with those of a previous study by
Suh et al., who have reported that -SMA protein level in
fibroblasts increases significantly upon CLIC4 over
expression produced by infecting with recombinant
CLIC4 adenovirus [20]. Additionally, we found that
silencing CLIC4 reversed the up-regulation of angiogenic
factors, ie.: hepatocyte growth factor (HGF) and vascular
endothelial growth factor (VEGF) in TGF-1 or CMSKOV3
treated fibroblasts (Fig. 3E, F, G).
Angiogenesis plays a key role in tumour development by
supplying the tumour with oxygen and nutrients. Recent
data shows that myofibroblasts are the major cell type
expressing pro-angiogenic factors in cancer stroma such as
angiogenic factor VEGF [12]. In this study EGF CMSKOV3 or
TGF-1 activated myofibroblasts have higher levels of
expressions of HGF and VEGF when compared to inacti-
vated fibroblasts (Fig. 3). Pre-treatment with a chloride
channel inhibitor IAA-94 to block function of CLIC4 low-
ered HGF and VEGF expression levels in myofibroblasts
by 24% - 80%. Furthermore, after fibroblasts were
relieved from these treatments, exposure to CMSKOV3 or
TGF-1 restored the expression of factors related to the
phenotype and functions of myofibroblasts (data not
shown), indicating these repressing activities were due to
the activation by CMSKOV3 or TGF-1, and were not mere
cytotoxic effects.
Conclusion
Ovarian cancer, like most solid tumours, not only
acquires adaptive mutations during therapy, but interacts
with myofibroblasts, thus promoting further growth and
metastasis. Because myofibroblasts are genetically morePage 4 of 8
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Molecular Cancer 2009, 8:78 http://www.molecular-cancer.com/content/8/1/78ROS-mediated up-regulation of CLIC4 expression during myofibroblast transdifferentiationFigure 2
ROS-mediated up-regulation of CLIC4 expression during myofibroblast transdifferentiation. (A) CMSKOV3 and 
TGF-1 induced oxidative stress in MRC-5 fibroblasts using DCF-DA analysed by fluorescent microscopy. Scale bar, 50 m. (B, 
C), Myofibroblast transdifferentiation was dependent on ROS. The expression of -SMA and CLIC4 was determined by real 
time RT-PCR and Western blot, using MRC-5 cells treated with or without 5 mM of antioxidant (NAC), before addition of 
CMSKOV3 and TGF-1. * P < 0.05. (D), ROS mediated up-regulation of CLIC4 expression in both cytoplasm and nucleus during 
myofibroblast transdifferentiation. CLIC4 protein expression in cytoplasm and nucleus was determined by Western blot analy-
sis. Fibroblasts cultured in serum-free medium served as control for all the experiments.
 
stable than cancer cells, therapeutic targeting of these
myofibroblasts in the stroma has distinct advantage and
potential. In this study, we showed that treatment of
myofibroblasts with agents blocking ROS or CLIC4 can
reverse the phenotype of myofibroblasts, and markedly
repress the production of angiogenesis factors associated
with myofibroblast transdifferentiation, indicating that
ROS or CLIC4 are excellent targets for the development of
targeted molecular therapies for the treatment of ovarian
cancer.
Materials and methods
Cell culture and in vitro culture models
Both human epithelial ovarian cancer cell line SKOV3 and
human foetal lung fibroblast cell line MRC-5 were
obtained from Basic Medicine Research Institute, Qilu
Hospital, Shandong University, P.R. China. Human ovar-
ian primary fibroblasts were isolated as described previ-
ously [25]. These cells were cultured in DMEM (Gibco)
containing 10% heat-inactivated foetal bovine serum
(Gibco) and 100 units/ml penicillin/streptomycin. The
cultures were maintained at 37°C in an atmosphere of 5%
CO2. The purity of primary stromal cells was more than
98% confirmed by keratin and vimentin staining [26].
Ovarian fibroblasts between passage 3 and 8 were used for
all experiments.
Treatment of cells with TGF-1, conditioned medium from 
SKOV3 (CMSKOV3), N-acetyl-L-cysteine (NAC) or IAA-94
After SKOV3 cells were cultured in serum-free medium for
48 h, the conditioned medium were collected, clarified by
centrifugation and stored at -20°C for future use.
When MRC-5 cells and human ovarian primary fibrob-
lasts reached subconfluence, the medium was replaced by
serum-free medium, serum-free medium with 10 ng/ml
human recombinant TGF-1 (PeproTech EC Ltd., UK) or
CMSKOV3, then cultured for another 48 hours. In order to
study the inhibitory functions of NAC and IAA-94, sub-
confluent fibroblasts were incubated with 5 mM NAC for
4 hours or 10 M IAA-94 for 24 hours before addition of
TGF-1 or CMSKOV3.
Immunochemical and immunofluorescent staining
For immunohistochemical staining, the sections were
deparaffinized, and rehydrated followed by antigenPage 5 of 8
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Specific inhibition of CLIC4 expression stops myofibroblast transdifferentiation to fibroblastFigure 3
Specific inhibition of CLIC4 expression stops myofibroblast transdifferentiation to fibroblast. MRC-5 cells were 
transfected with specific CLIC4 siRNA and then treated with or without CMSKOV3 and TGF-1. Mock transfection with trans-
fection reagent alone and scrambled siRNA (neg siRNA) served as negative controls. The relative levels of CLIC4 (A), -SMA 
(B) transcripts and -SMA protein expression were assessed by real time RT-PCR, Western blot (C) and immunofluorescent 
staining (D). Scale bar, 50 m. Quantitative RT-PCR was used to analyse transcription levels of pro-angiogenic factors, VEGF 
(E), HGF (F) and -SMA (G) in MRC-5 cells treated with chloride channel inhibitor IAA-94, NAC or CLIC4 siRNA before addi-
tion of CMSKOV3 and TGF-1. * P < 0.05.
 
Molecular Cancer 2009, 8:78 http://www.molecular-cancer.com/content/8/1/78retrieval. The cells were fixed with 3.7% formaldehyde for
immunocytochemical analysis. Afterwards, these sections
and cells were blocked with 10% normal goat serum, and
then incubated with rabbit anti-CLIC4 polyclonal anti-
body (Lifespan Biosciences, USA) and rabbit anti--SMA
monoclonal antibody (Abcam, UK) at 4°C overnight,
respectively. After washing with PBS, the slides were incu-
bated with anti-rabbit IgG secondary antibody for 45 min
and then incubated with biotinylated horseradish peroxi-
dase solution for 45 min. Finally, the slides were stained
with diaminobenzidine and observed under light micro-
scope. For immunofluorescent staining, cells were stained
with FITC conjugated anti-rabbit IgG secondary antibody,
and nuclei were stained with 4,6-diamidino-2-phenylin-
dole (DAPI). Images were recorded using confocal micro-
scope.
Western blot analysis
Cells were lysed in RIPA lysis buffer plus protease inhibi-
tors. Cell nuclear and cytoplasmic proteins were extracted
using Nuclear/Cytosol Extraction Kit (Pierce Biotechnol-
ogy, Inc., USA). The expressions of CLIC4 and -SMA
were characterized by Western blot using polyclonal anti-
CLIC4 antibody and monoclonal anti--SMA antibody as
primary antibodies. Reaction products of -actin were
used to normalize the intensities between lanes.
Analysis of intracellular ROS
The intracellular ROS generation was assayed using 2'-7'-
dichlorofluorescein diacetate (DCF-DA) (Sigma) dye as
previously described [10].
Small interfering RNA (siRNA) transfection
The siRNAs used in this study were designed, functional
tested by and purchased from Qiagen. The sequences of
siRNA were as follows: CLIC4 validated siRNA 5'-GCA-
GUACAAUGAU UAGUAAdTdT-3' (sense) and 5'-UUAC-
UAAUCAUUGUACUGCdTdA-3' (antisense); negative
Control siRNA 5'-UUCUCCGAACGUGUCACGUdTdT-3'
(sense) and 5'-ACGUGACACGU UCGGAGAAdTdT-3'
(antisense); MAPK1 positive control siRNA 5'-UGCU-
GACUCCAAA GCUCUGdTdT-3' (sense) and 5'-
CAGAGCUUUGGAGUCAGCAdTdT-3' (antisense). Lipo-
fectamine 2000 reagent was used for transfection with a
final concentration of 30 nM of each siRNA. After 16
hours of incubation of transfection, cells were replaced
with serum-free medium with or without 10 ng/ml TGF-
1 or CMSKOV3 and then incubated for another 48 hours.
Real-time Quantative Polymerase Chain Reaction
Total RNA was extracted from cells using Trizol reagent
(Invitrogen). RNA was reverse transcribed with oligo (dT)
and M-MLV reverse transcriptase (Promega). The primers
were designed as follows: -SMA (accession no.
NM_001613), 5'-AGGTAACGAGTCAGAGCTTTGGC-3'
(forward) and 5'-CTCTCTGTCCACCTTCCAGCAG-3'
(reverse); CLIC4 (accession no. NM_013943), 5'-CACG-
TAAATTTCTGGATGGCAATG-3' (forward) and 5'-
ATCACTGGGACAGGTATTGGTGAAC-3' (reverse); VEGF
(accession no. NM_001025366), 5'-CCTGGTGGA-
CATCTTCCAGGAGTACC-3' (forward) and 5'-GAAGCT
CATCTCTCCTATGTGCTGGC-3' (reverse); HGF (acces-
sion no. NM_000601), 5'-GTAAATG GGATTCCAACAC-
GAACAA-3' (forward) and 5'-
TGTCGTGCAGTAACAACCAACTC-3' (reverse); -actin
(accession no. NM_001101), 5'-AACTCCATCATGAAGT-
GTGA-3' (forward) and 5'-ACTCCTGCTTGCTGATCCAC-
3' (reverse). -actin was chosen as the house keeping gene.
The quantification was performed using SYBR Green
(Takara Biotechnology, Inc., Japan). Samples were ana-
lysed using LightCycler® 2.0 Instrument (Roche Applied
Science, Switzerland).
Statistical analysis
The data represented means ± S.D. of three independent
experiments. Statistical differences were analysed with the
Student's t-test. Differences were considered significant at
P-values < 0.05.
List of abbreviations
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fering RNA; TGF-1: transforming growth factor-1
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